HIM
ENZ

Hillsdale Investment Management’s Enzo Biochem, Inc. ENZ Stock Holding History

Hillsdale Investment Management’s Portfolio ENZ Stock Details ENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-15,100
Closed -$167K – 535
2017
Q2 		$167K Buy
+15,100
New +$141K 0.03% 290
2016
Q3 		– Sell
-14,300
Closed -$85K – 565
2016
Q2 		$85K Buy
+14,300
New +$79.4K 0.02% 324

Other funds holding ENZ

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EGA
Evermore Global Advisors Summit, New Jersey $26.3M AUM 7.42% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Hillsdale Investment Management's ENZ Position: Q3 2017 in Review

Hillsdale Investment Management sold out of Enzo Biochem, Inc. (ENZ) in Q3 2017, closing a stake of 15,100 shares — an estimated $167K sold.

Hillsdale Investment Management first reported a position in ENZ in Q2 2016 and held it in 2 quarters. The position peaked at $167K in Q2 2017. 116 funds tracked by Wall St. Rank hold ENZ as of Q3 2017.

  • Hillsdale Investment Management reported no remaining Enzo Biochem, Inc. position as of Q3 2017 after selling out during the quarter.
  • Hillsdale Investment Management sold 15,100 Enzo Biochem, Inc. shares in Q3 2017, an estimated $167K.
  • Hillsdale Investment Management first reported a position in Enzo Biochem, Inc. in Q2 2016 and held it in 2 quarters.
  • Hillsdale Investment Management's Enzo Biochem, Inc. position peaked at $167K in Q2 2017.
  • 116 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q3 2017.

Based on Hillsdale Investment Management's 13F filing for Q3 2017, filed 13 Nov 2017.